Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Wednesday

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $12.78 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.82 during trading on Friday, hitting $9.69. 1,490,801 shares of the company were exchanged, compared to its average volume of 911,426. The company has a fifty day moving average price of $15.45 and a 200-day moving average price of $19.86. The firm has a market capitalization of $738.73 million, a PE ratio of -3.35 and a beta of 2.23. Nurix Therapeutics has a 12-month low of $9.45 and a 12-month high of $29.56.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last ninety days. 7.20% of the stock is owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Stephens reaffirmed an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Morgan Stanley upped their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, Leerink Partners initiated coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.88.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.